Clinuvel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Clinuvel Pharmaceuticals has a total shareholder equity of A$203.0M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$231.1M and A$28.1M respectively. Clinuvel Pharmaceuticals's EBIT is A$48.6M making its interest coverage ratio -16.9. It has cash and short-term investments of A$183.9M.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | -16.9x |
| Cash | AU$183.87m |
| Equity | AU$203.01m |
| Total liabilities | AU$28.11m |
| Total assets | AU$231.12m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: UR9A's short term assets (A$222.1M) exceed its short term liabilities (A$25.2M).
Long Term Liabilities: UR9A's short term assets (A$222.1M) exceed its long term liabilities (A$2.9M).
Debt to Equity History and Analysis
Debt Level: UR9A is debt free.
Reducing Debt: UR9A has not had any debt for past 5 years.
Debt Coverage: UR9A has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: UR9A has no debt, therefore coverage of interest payments is not a concern.